Please provide your email address to receive an email when new articles are posted on . Medtronic announced that it has begun enrollment for a feasibility study assessing the safety and efficacy of a ...

NEW YORK-- Nov. 20, 2013 -- The first device of its kind to undergo clinical evaluation in the United States, the Valiant "Mona LSA" branch thoracic stent graft system from Medtronic, Inc. (MDT) has ...

Investigational Device Enables Endovascular Repair of Aortic Aneurysms Encroaching on Left Subclavian Artery DUBLIN, Medtronic plc today announced the start of a new feasibility study to evaluate the ...

Medtronic is developing a version of its Valiant stent graft for the left subclavian artery.--Courtesy of Medtronic Medtronic ($MDT) is touting some positive early ...

Medtronic (NYSE:MDT) announced on Thursday that a stent graft to treat thoracic aortic aneurysms is one of nine devices part of a pilot program at the U.S. Food and Drug Administration aimed to help ...

Medtronic (MDT) demonstrated proof of concept for its Valiant Mona LSA branch thoracic stent graft system. The medical device company announced the results of its “Innovation Pathway” feasibility ...

Presented at VEITH, Acute Results from Initial Trial of New Medical Technology Show Promise for Endovascular Approach to Thoracic Aortic Aneurysms Involving Left Subclavian Artery The early ...

DUBLIN -- April 21, 2015-- Medtronic plc (MDT) today announced the start of a new feasibility study to evaluate the safety and effectiveness of the Valiant Mona LSA branch thoracic stent graft system, ...